What question did this study set out to answer?

The study aims to explore patient experiences and perceptions regarding GLP-1 receptor agonists for weight loss, to enhance obesity care approaches.

May 9, 2026Open Access

275 Patient perspectives on GLP-1 receptor agonists for weight loss: A mixed-methods study to inform translational obesity care

Key Points

The study aims to explore patient experiences and perceptions regarding GLP-1 receptor agonists for weight loss, to enhance obesity care approaches.
Mixed-methods approach with 140 adults completing surveys and semi-structured interviews.
Participants were grouped based on their experiences with GLP-1 therapies, with a focus on various aspects of their treatment journey.
Qualitative data was thematically analyzed using Dedoose, while quantitative data was assessed using SAS.
Distinct themes emerged, such as reduced interest in food among active users (Group 2).
Participants (Group 4) reported success with GLP-1 but expressed concerns over medication access due to cost and insurance.
Some participants discontinued treatment due to side effects or financial barriers, highlighting varying access to educational support from clinicians.

Abstract

Objectives/Goals: To explore patient experiences and perceptions of GLP-1 receptor agonists for weight loss, informing translational obesity care and highlighting the impact of emerging therapies on patient-centered outcomes. Methods/Study Population: This mixed-methods study included adults (≥18 years) without diabetes, pregnancy, or relevant medical contraindications. From March to July 2025, 140 participants completed a 30-item survey and ~30-question semi-structured interview tailored to six distinct GLP-1 experience groups from considering it, to actively using it, to having stopped. Participants received a 20 e-gift card. Quantitative data were analyzed using SAS; qualitative data were coded and thematically analyzed in Dedoose. The sample was predominantly white (82%), female (63%), privately insured (84%), employed full-time (74%), college-educated (75%), and married (65%), with 47% reporting income ≥100, 000 and a mean age of 45 years. Results/Anticipated Results: Distinct themes emerged across groups. Group 2 reported reduced interest in food, which influenced their food choices with mixed clinician support on nutrition. Group 4 credited GLP-1 for weight loss success but feared losing access to medication due to cost or insurance and thereby rebounding. Group 6 discontinued due to unsustainable side effects, cost, or coverage denial. Female participants (Groups 3–5) often faced stigma, with comments about “cheating” in weight loss, rarely reported by males. A reduction in “food noise” – intrusive food thoughts – was common while on GLP-1. Educational support from clinicians varied widely. Despite media portrayals, nearly all participants had long struggled with weight and were actively pursuing healthy lifestyles with exercise and nutritious food while on GLP-1. Discussion/Significance of Impact: Findings reveal strong patient enthusiasm for GLP-1 therapies and emphasize the need for consistent education and policy reform to support equitable, sustainable obesity care. Patient-centered insights can inform translational strategies in obesity treatment.

Perguntar à IA

Bookmark

View Full Paper